Literature DB >> 2883238

Epidemiology of human T cell leukemia virus type I infection in East Sepik Province, Papua New Guinea.

J W Kazura, W C Saxinger, J Wenger, K Forsyth, M M Lederman, J A Gillespie, C C Carpenter, M A Alpers.   

Abstract

A serological survey of 317 healthy residents of rural Papua New Guinea (PNG) showed a 26% prevalence of antibodies to human T cell leukemia virus type I (HTLV-I). Antibody to HTLV-I was detected in 16% of children less than or equal to 10 years old (including an 18-month-old child) and increased to greater than or equal to 24% in subjects greater than 20 years old. Prospective examination for antibody in 104 residents of one village revealed a seroconversion rate of 13% over a one-year period. The mean titer of antibody in these subjects (1:183) was lower (P less than .0005) than that in persons who were persistently seropositive (1:718). Analysis for clustering of infected subjects suggested that personal contact within the home played a role in the horizontal spread of HTLV-I. These data indicate that HTLV-I infection has a higher prevalence in PNG than in other endemic parts of the world, exposure occurs at an early age, and infection and/or seroconversion is common in adults as well as in children.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883238     DOI: 10.1093/infdis/155.6.1100

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  HTLV-I antibody studies in villagers in East Sepik Province, Papua New Guinea.

Authors:  R C Sanders; A Levin; G Anian; I Webber; H Lee; P Swanson; A Diwan; R Desowitz; W A Blattner; M P Alpers
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 2.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

Review 3.  The origin and evolution of human T-cell lymphotropic virus types I and II.

Authors:  Y Suzuki; T Gojobori
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

4.  The prevalence of antibodies to human T-lymphotropic virus type I in different population groups in Papua New Guinea.

Authors:  R C Sanders; P M Wai'in; S S Alexander; A G Levin; W A Blattner; M P Alpers
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 5.  Human T-lymphotropic virus type I (HTLV-I) and tropical spastic paraparesis or HTLV-I-associated myelopathy in Hawaii.

Authors:  P S Dixon; A J Bodner; M Okihiro; A Milbourne; A Diwan; J M Nakamura
Journal:  West J Med       Date:  1990-03

6.  Highly divergent molecular variants of human T-lymphotropic virus type I from isolated populations in Papua New Guinea and the Solomon Islands.

Authors:  A Gessian; R Yanagihara; G Franchini; R M Garruto; C L Jenkins; A B Ajdukiewicz; R C Gallo; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

7.  Isolation of a human T-lymphotropic virus type I strain from Australian aboriginals.

Authors:  I Bastian; J Gardner; D Webb; I Gardner
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

8.  Antenatal survey for the seroprevalence of HTLV-1 infections in the West Midlands, England.

Authors:  S Nightingale; D Orton; D Ratcliffe; S Skidmore; J Tosswill; U Desselberger
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

9.  Characterization of a variant of human T-lymphotropic virus type I isolated from a healthy member of a remote, recently contacted group in Papua New Guinea.

Authors:  R Yanagihara; V R Nerurkar; R M Garruto; M A Miller; M E Leon-Monzon; C L Jenkins; R C Sanders; P P Liberski; M P Alpers; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

10.  HTLV-I, HIV-I, and hepatitis B and C viruses in Western Province, Papua New Guinea: a serological survey.

Authors:  K Yamaguchi; T Inaoka; R Ohtsuka; T Akimichi; T Hongo; T Kawabe; M Nakazawa; M Futatsuka; K Takatsuki
Journal:  Jpn J Cancer Res       Date:  1993-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.